Intradigm

Intradigm Corporation was an American biotechnology company based in Rockville, Maryland.

Intradigm was founded in mid-2000 by Jill Glasspool-Malone, Jim Mixson and Martin Woodle.¹⁾ The company's non-viral gene delivery technology was originally developed by Genetic Therapies, Inc. (GTI) and licensed to Intradigm by Novartis after their several attempts at gene therapy failed.²⁾ The license agreement was transferred to Intradigm contingent on funding from Emerging Technology Partners and Novartis’ own venture fund.

Glasspool-Malone began working on the startup in August 1999 as Managing Director, helping to secure $2.3 million in venture capital funding, setting up laboratory and office facilities, and developing the company's scientific and business development plan.³⁾ Intradigm entered the State of Maryland's Challenge Investment Fund program on September 20, 2000.

Intradigm closed its Series A round of funding in June 2001, receiving a $300,000 investment from the Maryland Venture Fund (MVF).⁴⁾ The company “entered in to a multi-year, multi-product development program” with DirectGene in December 2001 to “jointly develop products aimed at prostate and pancreatic cancer.”⁵⁾

On November 22, 2002, Itradigm announced it had hired former Novavax CEO John Spears as its Chairman and CEO.^{6) 7)}

On December 16, 2009, Intradigm was acquired by Silence Therapeutics.⁸⁾

Investors in Intradigm include:^{9) 10)}

• Alta Partners
• Astellas Venture Management
• Eli Lilly
• Emerging Technology Parters
• Frazier Healthcare Partners
• Maryland Venture Fund
• MediBIC Group
• MP Healthcare Venture Management
• Novartis Venture Fund
• Roche Venture Fund

• Housatonic